Register Log-in Investor Type


QuotedData’s morning briefing 28 June 2022

In QuotedData’s morning briefing 28 June 2022:

  • Pharmakon Advisors, the investment manager of BioPharma Credit (BPCR)  says that it notes the announcement released yesterday by Ipsen regarding its planned purchase of Epizyme Inc. BioPharma Credit has a $110m investment in a senior secured loan to Epizyme which would be prepaid upon the closing of the deal. The loan was made in four different tranches with each tranche having a different prepayment economics. Depending on the actual timing of the prepayment, the fund would be expected to receive between $3m to $7m in prepayment and make-whole fees. [This is good news for the fund. For a fuller explanation of the upside to BioPharma Credit of being repaid early we suggest you watch last Friday’s interview with the fund’s manager.]
  • Apax Global Alpha (APAX) says that it will commit $700m to the new Apax XI Fund. The commitment is expected to be split 70:30 between the USD and Euro tranches of the fund. Apax XI will invest in buyout opportunities globally across four core sectors: technology, services, healthcare and internet/consumer.

We also have an acquisition update from NextPower III ESG, the private fund backed by NextEnergy Solar

previous story | next story

Leave a Reply

Your email address will not be published. Required fields are marked *

Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.

You live in…

You are a…